Loading, Please Wait...
SEATTLE, April 08, 2019 (GLOBE NEWSWIRE) -- Alexander W. Casdin, Founder, CEO, and Portfolio Manager of Reneo Capital Management LP, has been named to the Board of Directors of Receptor Holdings (RHI). Mr. Casdin has a proven record of success in healthcare business investments and over 20 years of experience in corporate leadership roles.
"Alex is one of the most respected investors in today’s biopharmaceutical industry,” said Greg Wesner, CEO, Receptor Holdings. “His long track record of investment and corporate success provides a wealth of experience coupled with the trust and respect of scientists, pharmaceutical executives, and investors. We’re thrilled to have Alex join Receptor Holdings’ Board of Directors.” Mr. Casdin added, “I am extremely pleased to be joining Receptor Holdings Board, as I firmly believe Receptor’s developing product portfolio will disrupt the cannabinoid space. By leveraging patented, proven drug delivery technologies, Receptor’s products have the potential to improve and expand the therapeutic utility of cannabinoid medicines.”
Alex currently is a Board Member of Erasca and DiaVacs and serves on the Advisory Board of Luna DNA. He also previously served as a Board member of Ignyta and Dusa Pharmaceuticals until their respective acquisitions by Roche and Sun Pharma. Alex’s operational leadership roles have included Chief Financial Officer of Sophiris Bio and Vice President, Finance at Amylin Pharamceuticals. Prior to that he founded and ran Casdin Advisors LLC, providing strategic advice to life science companies, including Amylin. Alex was Chief Executive Officer and Portfolio Manager of Cooper Hill Partners LLC, a healthcare investment fund. Before that, his credentials include Portfolio Manager of Pequot Capital Management’s healthcare fund; and Senior Managing Analyst covering pharmaceuticals, biotechnology and medical devices at Dreyfus Corporation. Alex also served as a Legislative Assistant to Congressman Robert J. Mrazek (D-NY) and Legislative Affairs Specialist for Patton Boggs LLP in Washington, D.C.
He is a strong supporter of the clinical research community as an Executive Committee and Board Member of The Conquer Cancer Foundation of the American Society of Clinical Oncology and Advisory Board member of the Hassenfeld Children’s Center for Pediatric Oncology and Blood Disorders at NYU Langone Medical Center. Alex is also member of the External Advisory Board for the Center for Biomedical Engineering at Brown University’s School of Engineering, and Brown’s President’s Leadership Council. He holds an A.B. in Political Science from Brown University and an M.B.A., Beta Gamma Sigma, from Columbia Business School.
ABOUT RECEPTOR HOLDINGS AND RECEPTOR LIFE SCIENCES
Seattle-based RHI owns or has exclusively licensed drug delivery technologies characterized by high bioavailability, rapid onset of action and low variability. These technologies are being leveraged to develop both prescription and over-the-counter cannabinoid medicines for the U.S. and global markets.
Receptor Life Sciences, Inc. (RLS), is a subsidiary of RHI focused on FDA-regulated drug development. RLS will use RHI drug delivery technologies to develop cannabinoid medicines across a range of therapeutic indications.
For more information please visit www.receptorlife.com .
Contact: David Sheon 202 422-6999 Email: email@example.com